PCSA Processa Pharmaceuticals, Inc.

Nasdaq processapharmaceuticals.com


$ 0.34 $ -0.01 (-1.73 %)    

Wednesday, 05-Nov-2025 15:59:45 EST
QQQ $ 623.20 $ 4.94 (0.8 %)
DIA $ 473.36 $ 2.23 (0.47 %)
SPY $ 678.05 $ 2.47 (0.37 %)
TLT $ 88.96 $ -0.57 (-0.64 %)
GLD $ 365.20 $ 0.10 (0.03 %)
$ 0.34
$ 0.35
$ 0.32 x 400
$ 0.33 x 2,860
$ 0.31 - $ 0.36
$ 0.15 - $ 1.50
5,107,576
na
17.12M
$ 0.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-06-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-28-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-21-2018 03-31-2018 10-Q
31 04-16-2018 12-31-2017 10-K
32 11-20-2017 09-30-2017 10-Q
33 10-04-2017 06-30-2017 10-Q
34 10-04-2017 03-31-2017 10-Q
35 09-25-2017 12-31-2016 10-K
36 09-08-2017 09-30-2016 10-Q
37 08-30-2017 06-30-2016 10-Q
38 08-07-2017 03-31-2016 10-Q
39 06-19-2017 12-31-2015 10-K
40 12-01-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 processa-pharmas-abstract-adaptive-phase-23-study-for-pcs499-499-in-patients-with-focal-segmental-glomerulosclerosis-fsgs-accepted-for-presentation-at-asn-kidney-week-2025

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC...

 why-processa-pharmaceuticals-stock-rose-almost-38-overnight

Processa Pharmaceuticals shares jumped 37.5% after hours following a strong regular session, despite facing significant losses ...

 hc-wainwright--co-maintains-buy-on-processa-pharmaceuticals-lowers-price-target-to-1

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers th...

 processa-pharma-q2-eps-025-misses-020-estimate

Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0...

 processa-pharmaceuticals-signs-binding-term-sheet-granting-intact-therapeutics-an-exclusive-option-to-license-pcs12852-strengthens-balance-sheet-with-7m-capital-infusion

Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Ph...

 hc-wainwright--co-maintains-buy-on-processa-pharmaceuticals-lowers-price-target-to-2

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers th...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION